BiotechTube
Home/NapaJen Pharma/Kenji Arima
KA

Kenji Arima

CEO

NapaJen Pharma

Therapeutic Areas

ImmunologyOncologyInfectious DiseaseTransplant Medicine

NapaJen Pharma Pipeline

DrugIndicationPhase
NJA-730Undisclosed Immunological IndicationPhase 1